Evidence map›Paper›PMID 29946005›Full record

Trial reportThe European respiratory journal2018

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

Kevin R Flaherty, Charlene D Fell, J Terrill Huggins, Hilario Nunes, Robert Sussman, Claudia Valenzuela, Ute Petzinger, John L Stauffer, Frank Gilberg, Monica Bengus and 1 more

Erratum issuedOpen access · hybridAbstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The European respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Advances in idiopathic pulmonary fibrosis diagnosis and treatment.Chinese medical journal pulmonary and critical care medicine · 2025
    Review
  12. Review
  13. Article
  14. Review
  15. Understanding myofibroblast origin in the fibrotic lung.Chinese medical journal pulmonary and critical care medicine · 2024
    Review
  16. Article
  17. Targeted liposomes for macrophages-mediated pulmonary fibrosis therapy.Drug delivery and translational research · 2024
    Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Charlene D FellDivision of Respirology, University of Calgary, Calgary, AB, Canada.
J Terrill HugginsDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA.
Hilario NunesDept of Respiratory Medicine, EA2363, Avicenne University Hospital, Paris, France.
Robert SussmanAtlantic Health System, Overlook Medical Center, Summit, NJ, USA.
Claudia ValenzuelaServicio de Neumología, Hospital Universitario de La Princesa, Instituto de Investigación Princesa, Madrid, Spain.
Ute PetzingerClinipace-Accovion GmbH, Eschborn, Germany.
John L StaufferGenentech, Inc., South San Francisco, CA, USA.
Frank GilbergF. Hoffmann-La Roche, Ltd, Basel, Switzerland.
Monica BengusF. Hoffmann-La Roche, Ltd, Basel, Switzerland.
Marlies WijsenbeekDept of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Roche (Switzerland) · CHErasmus MC · NLHospital Universitario de La Princesa · ESMedical University of South Carolina · USOverlook Medical Center · USUniversité Sorbonne Paris Nord · FRUniversity of Calgary · CAUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed safety and tolerability of treatment with pirfenidone (1602-2403 mg·day

Indexed as

AgedAnti-Inflammatory Agents, Non-SteroidalDrug Therapy, CombinationFemaleHumansIdiopathic Pulmonary FibrosisIndolesInternationalityLungMaleMiddle AgedPyridonesTreatment OutcomeVital CapacityAnti-Inflammatory Agents, Non-SteroidalIndolesnintedanibpirfenidonePyridones

Identifiers

PMID29946005
PMCPMC6092682
OpenAlexW2810699055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.